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ABSTRACT
Background: Treatment strategy that reduces dependence on long-term medication for chronic asthma is
preferable. The purpose of the study is to investigate the efficacy of an early intensive intervention for inducing
inactive asthma in adults and identify factors that affect the efficacy.
Methods: A prospective study was conducted on subjects who had asthma for two years or less. An intensive
intervention consisting of systemic corticosteroid treatment for two weeks followed by inhaled corticosteroid for
further 16 weeks with concomitant administration of bronchodilator(s) was administrated on 109 subjects. As a
control group, 33 subjects were treated according to the current asthma treatment guidelines for 18 weeks. The
primary outcome of the intervention was assessed with symptomatology and use of medication during 12
months after the cessation of treatment period.
Results: At one year after the intervention, significantly more patients in the intensive intervention group (41%)
than in the control group (24%) had no respiratory symptoms and were medication-free or had experienced mi-
nor upper respiratory symptoms (inactive asthma) (P = 0.01). The intensive intervention maintained a signifi-
cant factor associated with one-year inactive asthma (adjusted odds ratio: 3.61, 95% confidence interval: 1.20-
10.84; P = 0.02). Infection as onset cause, asthma duration and pre-treatment %FEV1.0 were also identified in-
dependently associated with inactive asthma. As the limitation, the study was not randomized trial.
Conclusions: Intensive therapy in the early stage is very likely to contribute to increasing one-year asthma in-
activity, which may reduce patients’ dependence on long-term management by medical treatment.
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INTRODUCTION
Asthma patients who are faced with the prospect of
long-term treatment expect to have effective treat-
ments which could make asthma transient. Approxi-
mately 10% of adult asthmatics outgrow their asthma
over long-term observation.1 Early intervention using
high-doses of inhaled corticosteroid (ICS) has shown
a good prognosis for asthma.2,3 However, despite the
recent progress in asthma treatment, a definitive
strategy for inducing long-term inactive asthma has
not yet been reported. In this study, inactive asthma
is defined as symptom-free condition that does not re-
quire any medication for one year.
To address the issue of inducing inactive asthma,
we adopted the strategy that all asthmatics, regard-
less of onset mode, severity, and type of asthma in
the early stage, should be treated with a view to in-
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ducing inactive asthma using intensive treatment for
a longer period than usually prescribed, coupled with
early diagnosis of asthma and patient education. In
contrast to the current guidelines for asthma treat-
ment,4-6 which focus on establishing control of
asthma with medication, our approach uses the step-
down method from intensive treatment through ta-
pering and finally cessation of treatment regardless of
disease severity at the time of presentation. Our strat-
egy is driven by the hypotheses that airway inflamma-
tion may not be necessarily chronic at the onset of
asthma and that intensive strategic therapy with sys-
temic corticosteroids may be more effective for
achieving long-term inactive asthma if it is introduced
in the early stages of asthma. The present study is
not the comparison with International Asthma Guide-
lines for long-term management as the treatment
strategy.
We conducted a one-year follow-up study of an in-
tensive therapy for the early stage of asthma in adults
as a trial for assessing how to prolong the remission
period after cessation of intensive asthma treatment.
The objectives of the study were to evaluate the ef-
fectiveness of the early intensive intervention for
adult asthma in inducing inactivity in asthma over a
one-year period and identify factors that increased
the one-year inactivity rate.
METHODS
SUBJECTS
Patients who visited the outpatient department or
were admitted to the hospital during the period from
May 1997 to January 1999 and had asthma for less
than 2 years in duration were screened for enroll-
ment (n = 195). Both newly-diagnosed asthmatics and
previously-diagnosed asthmatics were included.
Patients who gave informed consent to undergo
the proposed treatment received the intensive proto-
col therapy (n = 112, median age, 44, [range, 17-73]).
Patients, who did not, received the standard therapy
as recommended in the guidelines (n = 35, median
age 42, [range, 19-73]).7-9
The protocol of this research was approved by the
ethics review board of the National Center for Global
Health and Medicine (NCGM). Verbal informed con-
sents from all patients were taken using the study ex-
planation note and recorded on the patients’ charts by
performed researchers. There was no obligation of
written informed consent at the time of study per-
formance and this process was approved by the ethi-
cal review board in NCGM (Ethical committee ap-
proval No. 127).
DIAGNOSTIC CRITERIA FOR ASTHMA FOR
STUDY ENROLLMENT
In accordance with the diagnostic criteria in the
GINA guidelines,8 patients were diagnosed with
asthma if they showed a 15% or greater within- and
between-day variation in peak expiratory flow (PEF)
and a 15% or greater improvement in PEF in response
to bronchodilator(s).
Bronchial hyperresponsiveness (BHR) was meas-
ured by methacholine provocation testing in each
participant, except those with unstable or severe
asthma at presentation. Positive BHR was defined as
provocation concentration of methacholine causing a
20% decrease in base-line of FEV1.0 (PC20) < 8.0 mg
mL.10,11
Subjects whose asthma onset was considered in-
sidious had airway symptoms such as cough, or spu-
tum or dyspnea for over one month and met the
above mentioned criteria for air-flow limitation as well
as positive BHR.
EXCLUSION CRITERIA FOR STUDY ENROLL-
MENT
Subjects were not eligible for enrollment if they had
any of the following diseases or conditions:
1. Post infectious bronchitis (acute bronchitis),
bronchiolitis, chronic bronchitis, pulmonary emphy-
sema or endo-bronchial tuberculosis.
Post-infectious bronchitis was diagnosed based
on its response to pharmacotherapy, which occasion-
ally included antibiotics for airway infection, with
disappearance of symptoms within one month of en-
rollment. Pulmonary emphysema was diagnosed
by chest high-resolution computed tomography
(HRCT)12 and decreased diffusion capacity on pulmo-
nary function tests (less than 80% of the predicted val-
ues). Bronchiolitis was diagnosed by characteristic
chest HRCT findings.12 Asthma patients who had
symptoms similar to those of cough variant
asthma13,14, but met the above mentioned diagnostic
criteria were enrolled. Gastroesophageal reflux disor-
der (GERD)15,16 was diagnosed based on the effec-
tiveness of proton pump inhibitor (PPI) or H2-
blockers, and little reversibility of PEF. However, pa-
tients who had asthma complicated by GERD were
enrolled.
2. Current heavy smokers with a smoking index of
400 or more. Smoking index was defined as the num-
ber of cigarettes per day multiplied by the number of
smoking years.
3. Occupational and drug-induced asthma for
which the etiological agent was known.
4. Recurrence of adult asthma from childhood
asthma with a inactive duration of less than 3 years.
5. Allergic bronchopulmonary Aspergillosis or my-
cosis, Churg-Strauss syndrome and pulmonary infil-
tration with eosinophils.
6. Subjects who concurrently suffered from diabe-
tes mellitus, or were at risk of becoming steroid-
induced diabetics, for example, those with obesity, or
a familial predisposition.
7. Subjects who were pregnant or wished to be-
come pregnant during the study period.
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ASTHMA ONSET MODE
Acute type was defined by dyspnea or severe cough
that occurred suddenly with an identifiable onset.
Chronic type was defined by airway symptoms, such
as cough, sputum or dyspnea that started insidiously
without an identifiable onset, but with a presumable
approximate duration.
INTENSIVE TREATMENT PROTOCOL
After an initial 1-2 week observation period for clinical
examinations, non-emergency patients who had
agreed to the intensive protocol were given oral corti-
costeroids (prednisolone, 0.5 mg or equivalentkg
day) for 2 weeks. A basic unit dose of prednisolone
was presumed to be 5 mg. Doses 2.5 mg or less were
scored as zero, and doses larger than 2.5 mg were
scored as 5 mg. Intravenous administration of hydro-
cortisone at a dose of 300 mg every 8 hours was
started in emergency cases and continued until the
patient’s condition improved and oral corticosteroid
administration became possible. Systemic administra-
tion of corticosteroids for 2 weeks was then switched
to inhaled beclomethasone dipropionate (BDP) at a
dose of 800 μgday for the next 8 weeks and then 400
μgday for the remaining 8 weeks with the aid of a
spacer. Other anti-asthma drugs, including bron-
chodilators or leukotriene receptor antagonists, were
administered during initiation of the therapy and anti-
biotics were given when a patient was found to have a
bacterial airway infection based on clinical judgment
and sputum culture. With the exception of the in-
haled corticosteroids, these drugs were stopped dur-
ing the course of treatment when the patients’ PEF
reached normal levels or symptoms of infection dis-
appeared. The conventional therapy including in-
haled corticosteroid, which was given to patients not
wishing to receive the intensive therapy, was adminis-
tered in accordance with the guidelines for asthma
severity.7-9 For patient education, all participating pa-
tients received verbal instructions and pamphlets
concerning the elimination and avoidance of environ-
mental risk factors and improving compliance with
medication.
TREATMENT PROTOCOL FOR RECURRENCE
ORWORSENING OF ASTHMA
In cases of non-acute exacerbation, recurrence or
worsening of asthma was defined as a greater than
10% decrease in PEF from the baseline value with res-
piratory symptoms of more than one week in dura-
tion. When these conditions were observed during
the treatment or follow-up period, the patient was
treated with 800 μgday of inhaled BDP for 2 weeks
followed by 400 μgday for the next 2 weeks as well
as appropriate bronchodilators. Acute exacerbations
were treated with systemic corticosteroids with bron-
chodilators for appropriate duration. After recovery,
the basal therapy was resumed.
PREVENTION OF SIDE EFFECTS OF SYSTEMIC
CORTICOSTEROIDS
During the first 2 weeks of treatment, patients were
simultaneously given a H2-blocker prophylactically.
Anti-hypertensive agents were also administered
when required and appropriate hypnotics were ad-
ministered when sleep disturbance manifested. After
2 weeks of systemic administration, patients were re-
quested to avoid physical stress for 1 week to allow
for recovery from adrenal suppression.17
STUDIES DURING THE TREATMENT COURSE
AND FOLLOW UP AFTER TREATMENT
Pulmonary function tests, bronchial provocation test-
ing, serum IgE, specific IgE antibodies, and the pe-
ripheral eosinophil blood count were examined be-
fore treatment and at 0, 6, and 12 months after treat-
ment. Daily PEF was recorded during the study. At
the end of the study, patients were face-to-face inter-
viewed or telephone interviewed using a structured
questionnaire and a questionnaire was sent by mail to
those who had stopped visiting the outpatient clinic.
CATEGORIZATION OF OUTCOME OVER 12
MONTHS
The outcome over the one-year period after the tenta-
tive cessation of any pharmacotherapy was catego-
rized into 3 groups (inactive, intermittent, and
chronic) according to 6 conditions on the basis of
clinical profiles.
Inactive
Condition 1: no respiratory symptoms and medica-
tion-free.
Condition 2: upper respiratory tract infections,
such as a common cold or short term respiratory
symptoms with a known trigger, but not requiring
anti-asthma drugs because symptoms and PEF recov-
ered within one week.
Intermittent
Condition 3: asthma transiently worsened for one
week or more, but the condition normalized following
a course of the rescue protocol.
Chronic
Condition 4: the rescue protocols were given twice
or more, or asthma symptoms reappeared after cessa-
tion of treatment.
Condition 5: asthma control required basic mainte-
nance therapy even after completion of pharmaco-
therapy.
Condition 6: asthma symptoms reappeared after
the patients elected to discontinue pharmacotherapy
and their decision to resume treatment or not was
made based on the mildness of the disease. Condi-
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Fig.　1　Study population. 195 cases were screened for enrollment. 147 cases were enrolled to the 
study. Finally 109 (85/24) cases for the intensive treatment group, 33 (27/6) cases for the guideline 
treatment group were evaluated for the one year outcome of prognosis. 24 cases in intensive treat-
ment group, 6 cases in the guideline treatment group respectively, evaluated by face-to-face or tele-
phone interview using the structured questionnaire.
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tion 6 was identified by interview using questionnaire
at the end of the one-year follow-up period.
STATISTICAL ANALYSIS
Patient characteristics were compared between the
intervention and control groups using unpaired t-test,
Pearson’s chi-square test, or Fisher’s exact test. The
one-year outcome for the two groups was compared
using the Mann-Whitney test. A univariate logistic re-
gression analysis was used to identify variables that
were significantly associated with the inactive asthma
outcome. A multivariate logistic regression analysis
was conducted to determine the effects of each pa-
tient characteristic on the efficacy of the intensive in-
tervention. The forward stepwise procedure was used
to develop a final model for predicting outcomes. The
fitness of the final model was investigated using the
Hosmer-Lemeshow test and by calculating receiver
operator characteristic (ROC) curves. The course of
PC20 from pre-treatment to 18 weeks after the end of
regimen and 12 months thereafter was recorded, and
the difference between two groups was compared us-
ing a mixed model. All P values are two-tailed with a
P value < 0.05 considered statistically significant.
Data analyses were conducted using PASW statistical
software (version 17; SPSS Inc. Chicago, IL, USA).
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Table　1　Pre-treatment patient characteristics
Intensive treatment group n = 109 Control group n = 33 P value*
Age ― yr 0.55
Median 44 42
Range 17-73 19-73
Male sex ― no.(%) 56 (51) 20 (61) 0.35
Allergic or asthma condition ― no. (%)
Type of asthma ― atopic 74 (68) 23 (70) 0.90
Other allergic diseases† 49 (45) 14 (42) 0.80
Complicating diseases‡ 69 (63) 15 (45) 0.07
Smoking 0.70
non smoker 41 (38) 15 (45)
ex-smoker 4 (5) 2 (6)
passive smoker 18 (17) 6 (18)
active current smoker 45 (41) 10 (58)
Indoor pet 43 (39) 9 (27) 0.20
Allergic disease in family 35 (32) 15 (45) 0.16
Asthma onset mode 0.25
chronic 71 (65) 25 (76)
acute 38 (35) 8 (24)
Infection as onset cause§ 71 (65) 20 (61) 0.64
Asthma duration ―month ± SD** 7.9 ± 7.8 8.1 ± 8.0 0.91
Condition at presentation 0.03
chronic 73 (67) 29 (88)
acute 35 (32) 4 (12)
Severity¶ 0.29
Severity I 11 (10) 6/33 (18)
Severity II 58 (53) 19/33 (58)
Severity III 35 (32) 7/33 (21)
Severity IV 4 (4) 0
Laboratory fi ndings 
Log IgE*** 5.5 ± 1.4 5.5 ± 1.3 0.87
Log Eos**** 5.9 ± 0.9 5.8 ± 0.8 0.75
%FVC#, ***** 96.2 ± 15.3 100.0 ± 17.8 0.26
%FEV1.0# 87.6 ± 19.6 91.7 ± 17.3 0.27
%PEFmin†† 69.9 ± 19.1 72.2 ± 15.4 0.65
Log PC20# 6.0 ± 1.6 6.1 ± 1.2 0.71
*P value were tested using Chi-square test or Fishers exact test.
Abbreviations: **SD, standard deviation; ***IgE, total IgE antibody in serum; ****Eos, count of peripheral eosinophil; *****FVC, forced vital 
capacity of volume.
† Allergic rhinitis, sinusitis, conjunctivitis, dermatitis.
‡ Alcohol induced asthma, exercise induced asthma, gastro-esophageal refl ux disorder.
§ Most infection episodes are viral infections diagnosed by symptonatology and clinical data. Three cases were post mycoplasma pneu-
monia infection.
¶Severity of the asthmatic condition was judged according to the classifi cation of long term severity for chronic state or of acute exacer-
bation for acute state in EPR II.7
# Severe or unstable cases are excluded that could not endure BHR and pulmonary function tests.
†† Minimum PEF was the minimum value of PEF during the observational period. %value of PEF is calculated by the standard values es-
tablished by the study of the normal Japanese population.23
Kudo K et al.
438 Allergology International Vol 60, No4, 2011 www.jsaweb.jp
Table　2　One year prognosis
Category No. (%) of the intensive treatment group n = 109
No. (%) of the control group 
n = 33
Inactive Condition 1 36 (33) 4 (12)
Condition 2 9 (8) 4 (12)
Total of conditions on 1, 2 45 (41) 8 (24)
Intermittent Condition 3 15 (14) 0 (0)
Chronic Condition 4 22 (20) 12 (36)
Condition 5 11 (10) 3 (9)
Condition 6 16 (15) 10 (30)
Total of conditions on 4, 5, 6 45 (45) 25 (75.8)
Mann-Whitney test; P = 0.01.
Prognosis during the one year after the cessation of any pharmacotherapy was categorized into six conditions.
Condition 1: no respiratory symptoms and medication-free.
Condition 2: upper respiratory tract infections symptoms but not requiring anti-asthma drugs.
Condition 3: asthma transiently worsened for one week or more, but normalized following a course of the rescue protocol.
Condition 4: the rescue protocols were given twice or more, or asthma symptoms reappeared after cessation of treatment.
Condition 5: asthma control required basic maintenance therapy after completion of medication.
Condition 6: asthma symptoms reappeared after the patients elected to discontinue medication.
RESULTS
STUDY POPULATION
Of the 195 subjects who were screened for enroll-
ment, 147 were eligible for the study. After excluding
the data of 5 subjects who dropped out of the study,
142 subjects (109 subjects comprised the intensive
treatment group, n = 109; control group, n = 33) were
enrolled for analysis (Fig. 1).
PATIENT CHARACTERISTICS
No significant difference in demographic and base-
line clinical characteristics were observed between
the intensive treatment and control groups, except in
terms of whether asthma condition at presentation
was acute or chronic (P = 0.03) (Table 1).
ONE-YEAR OUTCOME
The outcome during the one-year period folloing the
pharmacological therapy is shown in Table 2. Inactive
asthma at one year after treatment was achieved for
41% and 24% of the patients in the intensive treatment
group and the control group, respectively. However,
45% and 76% of patients in the intensive treatment
group and the control group, respectively, still had
chronic asthma. The prognosis of the intensive treat-
ment group was significantly better than the guide-
lines treatment group (P = 0.01). No serious side ef-
fects occurred on the patients under the treatment of
systemic corticosteroid for two weeks with preventive
medical care.
PATIENT CHARACTERISTICS ASSOCIATED
WITH INACTIVE ASTHMA AT ONE YEAR AFTER
TREATMENT
Patients’ pre-treatment characteristics, including both
treatment regimens in this study, were investigated
for association with inactive asthma at one year after
treatment (Table 3). Clinical background and labora-
tory data (history of allergy, obstructive pulmonary
disease, and BHR) were selected in consideration of
the pathophysiology of asthma. Intensive treatment
had an odds ratio of 2.20 (95% CI, 0.91-5.31) for inac-
tive asthma at one year after treatment. Some histo-
ries of illness, such as asthma onset mode, infection
as onset cause, and condition at presentation, were
also associated with outcome. Asthma duration
emerged as a significant factor affecting inactive
asthma at one year after treatment, with longer dura-
tions being less likely to result in inactive asthma (P <
0.01). Asthma severity tended to be associated with
inactive asthma, although this association was not sta-
tistically significant (P = 0.06). Results of pulmonary
function tests, such as %FVC and %FEV1.0, %PEFmin
and Log PC20, at the beginning of the treatment were
significantly associated with inactive asthma at one
year after treatment in patients who first presented
with a mild or stable condition that allowed them to
complete these tests. Thus, in patients with a mild or
stable condition, better pulmonary functions and less
BHR were indicators of a good prognosis (Table 3).
THE EFFECT OF INTERVENTION AFTER AD-
JUSTMENT
A multivariate logistic regression analysis was con-
ducted to determine the influence of possible con-
founding factors among patient characteristics in con-
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Table　3　Pre-treatment characteristics and their odds ratio for inactive asthma
Factor Odds ratio (95% confi dent interval) P value
Intensive intervention 2.20 (0.91-5.31) 0.008
Age - yr 1.00 (0.98-1.02) 0.72
Male sex 0.85 (0.43-1.68) 0.64
Type of asthma type (atopic /non-atopic) 0.82 (0.39-1.69) 0.58
Other allergic diseases † 0.94 (0.47-1.86) 0.86
Complicating diseases ‡ 0.96 (0.48-1.91) 0.90
Smoking 1.05 (0.82-1.35) 0.71
Indoor pet 1.23 (0.61-2.48) 0.57
Allergic disease in family 1.05 (0.51-2.13) 0.90
Asthma onset mode (acute/chronic) 0.34 (0.15-0.77) 0.01
Infection as onset cause§ 2.67 (1.24-5.74) 0.01
Condition at presentation (acute/chronic) 2.55 (1.20-5.43) 0.02
Asthma duration - month 0.81 (0.74-0.89) <0.01
Severity¶ I 2.67 (0.23-31.07)
Severity II 2.50 (0.25-25.12)
Severity III 0.82 (0.08-8.84)
Severity IV 1 0.06
Log IgE* 0.93 (0.73-1.20) 0.59
Log Eos** 0.86 (0.58-1.28) 0.45
%FVC#*** 1.03 (1.01-1.06) 0.01
%FEV1.0# 1.04 (1.02-1.07) <0.01
%PEFmin†† 1.03 (1.01-1.06) 0.01
Log PC20# 2.02 (1.46-2.79) <0.01
Abbreviations: *IgE, total IgE antibody in serum; **Eos, count of peripheral eosinophil; ***FVC, forced vital capacity of volume.
† Allergic rhinitis, sinusitis, conjunctivitis, dermatitis.
‡ Alcohol induced asthma, exercise induced asthma, gastro-esophageal refl ux disorder.
§ Most infection episodes are viral infections diagnosed by symptonatology and clinical data. Three cases were post mycoplasma pneu-
monia infection.
¶ Severity of the asthmatic condition was judged according to the classifi cation of long term severity for chronic state or of acute exacer-
bation for acute state in EPR II.7
# Severe or unstable cases are excluded that could not endure BHR and pulmonary function tests.
†† Minimum PEF was the minimum value of PEF during the observational period. %value of PEF is calculated by the standard values es-
tablished by the study of the normal Japanese population.23
Table　4　Adjusted odds ratio of intensive intervention and 
other pre-treatment characteristics for inactive asthma
Factor Odds ratio (95% confi dent interval) P value
Intensive intervention 3.61 (1.20-10.84) 0.02
Infection as onset cause† 2.99 (1.13-7.93) 0.03
Asthma duration (month) 0.85 (0.77-0.93) <0.01
%FEV1.0‡ 1.04 (1.01-1.07) <0.01
† Most infection episodes are viral infection diagnosed by symp-
tomatology and clinical data. Three cases were post mycoplasma 
pneumonia infection.
‡ Severe or unstable cases were excluded that were unable to 
endure pulmonary function tests.
sideration of the effect of the intensive treatment (Ta-
ble 4). After adjusting for possible confounding fac-
tors, the intensive intervention maintained a high
odds ratio of 3.61 (95% CI, 1.20-10.84; p = 0.02) for in-
active asthma at one year after treatment. Infection as
onset cause, asthma duration and %FEV1.0 were also
independently associated with inactive asthma. The
Hosmer-Lemeshow test of the final model had a p
value of 0.55 and the area under the ROC curve for
the model was 0.86 (95% CI, 0.79-0.92), indicating that
the model had good fitness.
BHR COURSE
The course of BHR was also compared between the
intensive intervention group and control groups (Fig.
2). The BHR of patients in the intensive treatment
group showed higher improvement at 18 weeks after
the treatment than the one of control group. The ef-
Kudo K et al.
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Fig.　2　Bronchial hyperresponsiveness course. The mean 
of PC20 of each group was indicated with vertical bars of the 
estimated standard errors. The course of BHR was com-
pared between the intensive intervention group and the con-
trol treatment group. The effect of intensive intervention was 
statistically signifi cant (p = 0.01 as an interaction of treat-
ment and time).
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fect of intensive intervention was statistically signifi-
cant (p = 0.01 as an interaction of treatment and
time). By the end of the one-year follow-up, the mean
value of PC20 in the intensive treatment group had
been maintained.
DISCUSSION
Approximately 10% of adult patients with asthma have
been reported to outgrow their asthma with treat-
ment.1 The current guidelines for asthma treatment
focus on establishing control of asthma with medica-
tion; therefore, improving our understanding of the
patient characteristics that indicate the potential for
remission, may allow us to induce inactive asthma in
a larger percentage of patients.
Previous early intervention therapy with high-dose
inhaled corticosteroid was unable to induce long-term
disease inactivity, although several cases of inactive
asthma have been reported.2 This may be because
the potency of even high-dose inhaled corticosteroid
alone might not have been sufficient for inducing in-
active asthma.18
The treatment protocol used in this study was de-
signed around an intensive drug regimen, namely
systemic corticosteroid administration for 2 weeks
switched to local corticosteroid administration for 16
weeks, to encompass treatment for all situations of
asthma onset. The 18-week duration of treatment
adopted in the study is comparable to the protocols
used for other respiratory diseases, in which most
cases are sent into remission, for instance; Bron-
chiolitis Obliterans Organizing Pneumonia19Crypto-
genic Organising Pneumonitis and Acute Eosino-
philic Pneumonia.20,21 The treatment was carried out
to avoid the adverse reactions associated with short-
term systemic administration. During the study pe-
riod, no serious side effects occurred under these
study conditions. Systemic corticosteroid administra-
tion for 2 weeks alone was not enough to achieve one-
year inactivity of asthma, as was demonstrated by the
cases that dropped out during the treatment course.
The present study identified the following four sig-
nificant factors that were associated with inactivity of
asthma at one year after treatment: intensive therapy,
infection as onset cause, asthma duration, and
%FEV1.0 (Table 4). Among these factors, early diagno-
sis and the intensity of the treatment are amenable to
physicians.
Overall, the intensive intervention used in this
study showed high efficacy. At one year after treat-
ment, 32 of 43 (74%) subjects who completed the in-
tensive treatment and whose asthma duration was 6
months or less had inactive asthma. Furthermore, 26
of 32 (81%) subjects who completed the intensive
treatment and whose asthma duration was 3 months
or less had inactive asthma at one year after treat-
ment. This strongly suggests that the early introduc-
tion of intensive treatment coupled with early diagno-
sis has a considerable impact on asthma prognosis.
Although the results of a multivariate logistic re-
gression analysis indicated that infection as onset
cause was also a good indicator for a favorable out-
come, it reamains unclear why this factor was impor-
tant.
In addition, %FEV1.0 was identified as an indicator
of good prognosis. Although data are only available
from patients who could complete the pulmonary
function tests at the time of presentation, even most
cases with severe and acute onset asthma at presenta-
tion had inactive asthma at one year after the early in-
tensive intervention. A previous report speculated
that %FEV1.0 is associated with prognosis1; thus, the
present findings seem to confirm the presence of an
association.
There are limitations to this study. First, this study
was not a randomized trial. Therefore, other possible
confounding factors could have affected the outcome,
even after adjustment. Second, this research was a
small-scale, single-center study. Consequently, the
number of subjects was not large enough to allow for
generalization. Third, as no gold standard diagnostic
criteria have been established for asthma, some pa-
tients in this study may not have developed chronic
asthma in the future. Although the new methods to
measure airway inflammations such as fraction of ex-
haled nitric oxide have been currently developed,22
no use those aspects for this study. In spite of these
limitations, the present findings suggest that the
early intensive intervention could induce inactive
asthma for one year.
The treatment strategy for adult asthma in early
Intensive Intervention for Early Asthma
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stage was proposed in the study. This strategy re-
quires early diagnosis and adequate treatment inten-
sity, and appears to be applicable regardless of
asthma severity at presentation. Our findings suggest
that early intensive intervention is effective for induc-
ing inactive asthma in adults. It assists to develop cer-
tain treatment strategies which can increase a rate of
outgrow in adult asthma with further large-scale, ran-
domized trials.
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